To the Editor:

We read with great interest the paper published by Nannan Panday et al. \[[@CR1]\], who reported that, first, culture-positive sepsis patients have a higher mortality rate than those with culture-negative and, second, culture-positive sepsis patients more often have multiple organ systems affected during the sepsis episode. Firstly, we compliment the authors for this very interesting study.

Nevertheless, to our opinion, some methodological issues deserve their attention. Firstly, the database used for the analysis comes from another study (PHANTASi trial) \[[@CR2]\], in which, eligible patients were those with a suspected of (severe) sepsis and septic shock \[[@CR2]\]. Thus, we cannot be certain that all included patients have sepsis rather than an alternative diagnosis. The authors do not report how many patients were septic or not; we cannot rule out that patient selection could be the biggest issue directly affecting the study results \[[@CR1]\]. Indeed, the blood culture results may be different if included patients were septic or not. This may also partly contribute to the negativity of the PHANTASi trial \[[@CR2]\].

Secondly, the variables included in the multivariate analysis (age, group allocation, hospital location, source of infection, antibiotics at home and total amount of blood cultures drawn) do not consider the potential cofounders of the in-hospital phase. Mortality is strongly affected by the in-intensive care unit and in-hospital length of stay due to their potential complications \[[@CR3]\]. For example, during the hospital stage, patients, especially elderly patients, may be affected by a limitation of care and/or nosocomial infection. Beyond these 2 methodological issues, we should keep in mind that, apart from source control, sepsis mortality is not only affected by antibiotherapy, but also by a bundle of care among which hemodynamic optimization plays an important role \[[@CR4], [@CR5]\].

Nevertheless, we fully agree that, contrary to septic shock, early identification of sepsis, especially those at risk of unfavourable evolution, is particularly difficult in the prehospital setting where the diagnosis is based on a list of non-specific physiological variables. The additional use of biomarkers, blood lactate measurement to assess severity and procalcitonin to confirm the bacterial origin of sepsis may be useful in order to define which patients should benefit from early prehospital antibiotic administration. Such a strategy enhancing better patients' selection could help the physician in the decision-making process and predict the real impact of early antibiotherapy.

This comment refers to the article available at 10.1186/s13054-019-2431-8.
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Dear editor,

We've read with interest the letter to the editor by Jouffroy et al. We would like to thank the authors for their valuable input and hereby our reaction to their comments.

Firstly, the authors state that perhaps not all patients included in our study had sepsis, but they may have an alternative diagnosis. As described in our study, all patients met SEPSIS-2 criteria at inclusion and retrospective chart analysis of all charts by a panel of experts (consisting of two acute physicians and one infectious disease specialist) was performed in order to exclude patients with an alternative diagnosis. This resulted in 1% of patients in the intervention group and 2% in the control group with a different diagnosis. Although these patients were included in both the PHANTASi trial and our (sub) study, we believe that such small numbers will not have had an effect on the outcomes \[[@CR1], [@CR2]\].

Secondly, Jouffroy et al. raise the point that potential in-hospital confounders, such as length of stay and nosocomial infections, should be part of the multivariate regression model used in our study. However, we believe hospital length of stay may be part of the causal pathway, i.e. patients with positive cultures have a higher sepsis severity, are more critically ill and therefore have to stay in hospital longer. As described by Jager et al., including covariates that are to be part of the causal pathway of the outcome in a model may lead to over-adjustment \[[@CR6]\]. Indeed, nosocomial infections are common in sepsis patients, although studies report a low attributable risk of mortality caused by nosocomial infections \[[@CR7]\]. We agree that superinfections should be considered as a covariate in future studies.

Apart from source control and antibiotic therapy, outcomes in septic patients are certainly effected by supportive care; however, hemodynamic optimization would mainly play a large role in septic shock patients, which were only approximately 4% of patients in our study cohort.

We agree with Jouffroy et al. that use of additional biomarkers, such as pro-calcitonin and lactate, in the (pre) hospital setting would guide emergency medical service personnel and clinicians to make a bacterial origin of infection more or less plausible. Currently, the level of the pro-calcitonin is not routinely measured in sepsis patients in the Netherlands, but this should be considered in the future. However, the role of procalcitonin in the emergency department setting is still a matter of debate.
